Table 5.
Main recalibration profiles highlighted by multiple correspondence analysis performed on the QLQ-BR23 for patients with recalibration
| N | Percentage of recalibration (number of patients retained) | Recalibration category 1 to category 2 | Recalibration category 2 to category 1 | Recalibration category 3 to category 2 | Recalibration category 3 to category 4 | Recalibration category 4 to category 3 | Categories 3 and 4 dispersed | ||
|---|---|---|---|---|---|---|---|---|---|
| Body image |
T1-T2_Ra |
68 |
29% (236) |
Q9-Q12 |
Q9-Q12 |
|
|
Q9, Q10 |
Q9-Q12 |
| (Q9-Q12) |
T1-T3_Rb |
119 |
50% (238) |
Q9-Q12 |
Q9-Q12 |
|
Q9, Q12 |
|
Q9-Q12 |
| |
T3-T4_Rc |
153 |
63% (244) |
Q9, Q10 |
Q9, Q10 |
|
|
|
Q9-Q12 |
| Sexual functioning |
T1-T2_R |
55 |
25% (219) |
Q14 |
|
Q14 |
|
|
|
| (Q14, Q15) |
T1-T3_R |
71 |
34% (210) |
Q14 |
|
Q14, Q15 |
|
|
|
| |
T3-T4_R |
78 |
37% (213) |
Q14, Q15 |
Q14, Q15 |
Q14, Q15 |
|
|
|
| Sexual enjoyment |
T1-T2_R |
13 |
13% (99) |
Q16 |
Q16 |
Q16 |
Q16 |
Q16 |
|
| (Q16) |
T1-T3_R |
39 |
39% (100) |
Q16 |
Q16 |
Q16 |
Q16 |
Q16 |
|
| |
T3-T4_R |
33 |
31% (108) |
Q16 |
Q16 |
Q16 |
Q16 |
Q16 |
|
| Future perspectives |
T1-T2_R |
122 |
47% (261) |
Q13 |
Q13 |
Q13 |
Q13 |
Q13 |
|
| (Q13) |
T1-T3_R |
135 |
52% (259) |
Q13 |
Q13 |
|
Q13 |
Q13 |
|
| |
T3-T4_R |
144 |
54% (269) |
Q13 |
Q13 |
|
Q13 |
Q13 |
|
| Systemic therapy side effects |
T1-T2_R |
55 |
26% (209) |
|
|
|
|
|
|
| (Q1-Q4, Q6-Q8) |
T1-T3_R |
61 |
32% (190) |
|
|
|
|
|
|
| |
T3-T4_R |
77 |
39% (200) |
|
|
|
|
|
|
| Breast symptoms |
T1-T2_R |
114 |
51% (223) |
Q20-Q23 |
Q20-Q23 |
|
|
|
Q20-Q23 |
| (Q20-Q23) |
T1-T3_R |
135 |
61% (223) |
Q20-Q23 |
Q20-Q23 |
Q20-Q23 |
|
Q20-Q23 |
Q20-Q23 |
| |
T3-T4_R |
190 |
74% (258) |
Q20-Q23 |
Q20-Q23 |
Q20-Q23 |
|
|
Q20-Q23 |
| Arm symptoms |
T1-T2_R |
97 |
38% (255) |
Q17-Q19 |
Q17-Q19 |
|
|
|
Q17-Q19 |
| (Q17-Q19) |
T1-T3_R |
111 |
46% (244) |
Q17-Q19 |
Q17-Q19 |
|
|
Q17 |
Q17-Q19 |
| |
T3-T4_R |
156 |
60% (260) |
Q17 |
Q17-Q19 |
|
|
|
Q17-Q19 |
| Hair loss |
T1-T2_R |
6 |
18% (34) |
Q5 |
|
Q5 |
|
Q5 |
|
| (Q5) |
T1-T3_R |
14 |
45% (31) |
Q5 |
|
Q5 |
Q5 |
Q5 |
|
| T3-T4_R | 24 | 44% (54) | Q5 | Q5 | Q5 | Q5 | |||
Only patients with a recalibration of 5-point at least between a pre-test and a then-test measure are incorporated in these analyses. Items with observed recalibration are listed.
aT1 → T2_R: comparison of baseline HRQoL assessment and retrospective measure performed after surgery.
bT1 → T3_R: comparison of baseline HRQoL assessment and retrospective measure performed three months later.
cT3 → T4_R: comparison of HRQoL assessment at three months and retrospective measure performed three months later.